# Tocilizumab

## Actemra inj 162mg/0.9mL

##### 臨採

| TAH Drug Code      | [IACTM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTM)                                                                                                                                                                                                                                                                                                          |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Moderate to severe active RA in adult patients, given alone or in combination w/ methotrexate (MTX) &/or other DMARDs.                                                                                                                                                                                                                                                          |
| Dosing             | SC, rheumatoid arthritis, giant cell arteritis: <100 kg 162 mg once every other week, increase to 162 mg once a week based on clinical response; > or =100 kg 162 mg once a week.                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to tocilizumab.                                                                                                                                                                                                                                                                                                                                                |
| Adverse Effects    | Upper resp tract infections, cellulitis, oral herpes simplex, herpes zoster; abdominal pain, mouth ulceration, gastritis; rash, pruritus, urticaria; headache, dizziness; increased hepatic transaminases, increased wt; HTN; leucopenia, neutropenia; hypercholesterolaemia; peripheral oedema, hypersensitivity reaction, inj site reaction; cough, dyspnoea; conjunctivitis. |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                   |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                      |

## Actemra Infusion 80mg/4mL/Vial (限Covid-19)

##### 臨採

| TAH Drug Code      | [IACTMV](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTMV)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | - Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have not responded to or cannot tolerate DMARDs or TNF antagonists. Can be used alone if MTX is unsuitable. - RA, MTX-naive: For adults with severe, active, progressive RA who have not received MTX. Can be used alone if MTX is unsuitable. - Polyarticular Juvenile Idiopathic Arthritis (PJIA): For patients aged 2 and older with active PJIA and inadequate response to MTX. Can be used alone if MTX is unsuitable. - Systemic Juvenile Idiopathic Arthritis (SJIA): For patients aged 2 and older with active SJIA who have not responded to or cannot tolerate NSAIDs and corticosteroids. - Cytokine Release Syndrome (CRS): For severe or life-threatening CRS caused by CAR T-cell therapy in patients aged 2 and older. - COVID-19: For hospitalized adults with COVID-19 who are on systemic corticosteroids and require oxygen support or mechanical ventilation, including ECMO.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | - COVID-19: Recommended dose for hospitalized adults: 8 mg/kg via a single 60-minute IV infusion, not exceeding 800 mg. May give an additional dose at least 8 hours after the first if symptoms worsen or don’t improve. Subcutaneous administration is not approved for COVID-19. - Rheumatoid Arthritis: Actemra can be used alone or with methotrexate (MTX). Recommended dose: 4 mg/kg intravenous (IV) infusion over 60 minutes Q4W; may adjust to 8 mg/kg based on clinical response. Adjust to 4 mg/kg if lab changes such as liver enzyme elevation, neutropenia, or thrombocytopenia occur. Do not exceed 800 mg per infusion. - Polyarticular Juvenile Idiopathic Arthritis (PJIA): Actemra can be used alone or with MTX. Recommended dose Q4W via 60-minute IV infusion: <30 kg: 10 mg/kg; >=30 kg: 8 mg/kg - Systemic Juvenile Idiopathic Arthritis (SJIA): Actemra can be used alone or with MTX. Recommended dose Q2W via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. - Cytokine Release Syndrome (CRS): IV administration only. Recommended dose for CRS via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. May administer up to 3 additional doses if no improvement, with at least 8 hours between doses. Do not exceed an 800 mg dose per infusion. Subcutaneous administration is not approved for CRS. - Avoid combination. No clinical data on combining Actemra with other biological DMARDs; risk of increased immunosuppression and infection. - Do not start Actemra in patients with ANC <2,000/mm^3 or 1000/mm^3 (COVID-19), platelet count <100,000/mm^3 or 50,000/mm^3 (COVID-19), or ALT/AST >1.5 times ULN or >10 times ULN (COVID-19). - Patients with severe/life-threatening CRS may have cytopenias or elevated ALT/AST due to chemotherapy or CRS. Evaluate benefits vs. risks of short-term Actemra use. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common: Hypertension (Adult, 4-7%), Injection site disorder (Rheumatoid arthritis, 2.4-10.1% ; polyarticular juvenile idiopathic arthritis, 28.8% ; systemic juvenile idiopathic arthritis, 41.2%), Rash (Rheumatoid arthritis, 2-4%), Constipation (COVID-19, 6-13%), Diarrhea (Adults, COVID-19, 4-6% ; Pediatric, >5%), Nausea (COVID-19, 3-4%), Upper abdominal pain (Adult, 2-3%), ALT/SGPT level raised (COVID-19, 3% ; rheumatoid arthritis, 0.7-48%; polyarticular or systemic juvenile idiopathic arthritis, 4-13%), Aspartate aminotransferase serum level above reference range (Rheumatoid arthritis, 0.1-41%; polyarticular or systemic juvenile idiopathic arthritis, <1-5%), Dizziness (Adult, 2-3%), Headache (Adults, 3-7%; pediatric, >5%), Insomnia (COVID-19, 4-5%), Anxiety (COVID-19, 3-6%), Nasopharyngitis (Rheumatoid arthritis, 4-7%; systemic juvenile idiopathic arthritis, 5% or higher), Infusion reaction (Rheumatoid arthritis, 7-8%; polyarticular juvenile idiopathic arthritis, 16-20.2%). Serious: Septic shock (COVID-19, 6%), Gastrointestinal perforation, Pancreatitis, Neutropenia (Rheumatoid arthritis, 1.8-3.7% ; polyarticular or systemic juvenile idiopathic arthritis, 7-15.4%), Thrombocytopenia (Up to 4%), Hepatotoxicity, Anaphylaxis, Hypersensitivity reaction (Up to 0.9%), Opportunistic infection, Tuberculosis, Upper respiratory infection (Rheumatoid arthritis, 6-8%; systemic juvenile idiopathic arthritis, 5% or higher), Cancer, Sepsis, Severe infectious disease.                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

## Actemra Infusion 200mg/10mL/Vial(限Covid-19)

##### 臨採

| TAH Drug Code      | [IACTMV10](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IACTMV10)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | - Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have not responded to or cannot tolerate DMARDs or TNF antagonists. Can be used alone if MTX is unsuitable. - RA, MTX-naive: For adults with severe, active, progressive RA who have not received MTX. Can be used alone if MTX is unsuitable. - Polyarticular Juvenile Idiopathic Arthritis (PJIA): For patients aged 2 and older with active PJIA and inadequate response to MTX. Can be used alone if MTX is unsuitable. - Systemic Juvenile Idiopathic Arthritis (SJIA): For patients aged 2 and older with active SJIA who have not responded to or cannot tolerate NSAIDs and corticosteroids. - Cytokine Release Syndrome (CRS): For severe or life-threatening CRS caused by CAR T-cell therapy in patients aged 2 and older. - COVID-19: For hospitalized adults with COVID-19 who are on systemic corticosteroids and require oxygen support or mechanical ventilation, including ECMO.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | - COVID-19: Recommended dose for hospitalized adults: 8 mg/kg via a single 60-minute IV infusion, not exceeding 800 mg. May give an additional dose at least 8 hours after the first if symptoms worsen or don’t improve. Subcutaneous administration is not approved for COVID-19. - Rheumatoid Arthritis: Actemra can be used alone or with methotrexate (MTX). Recommended dose: 4 mg/kg intravenous (IV) infusion over 60 minutes Q4W; may adjust to 8 mg/kg based on clinical response. Adjust to 4 mg/kg if lab changes such as liver enzyme elevation, neutropenia, or thrombocytopenia occur. Do not exceed 800 mg per infusion. - Polyarticular Juvenile Idiopathic Arthritis (PJIA): Actemra can be used alone or with MTX. Recommended dose Q4W via 60-minute IV infusion: <30 kg: 10 mg/kg; >=30 kg: 8 mg/kg - Systemic Juvenile Idiopathic Arthritis (SJIA): Actemra can be used alone or with MTX. Recommended dose Q2W via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. - Cytokine Release Syndrome (CRS): IV administration only. Recommended dose for CRS via 60-minute IV infusion: <30 kg: 12 mg/kg; >=30 kg: 8 mg/kg. May administer up to 3 additional doses if no improvement, with at least 8 hours between doses. Do not exceed an 800 mg dose per infusion. Subcutaneous administration is not approved for CRS. - Avoid combination. No clinical data on combining Actemra with other biological DMARDs; risk of increased immunosuppression and infection. - Do not start Actemra in patients with ANC <2,000/mm^3 or 1000/mm^3 (COVID-19), platelet count <100,000/mm^3 or 50,000/mm^3 (COVID-19), or ALT/AST >1.5 times ULN or >10 times ULN (COVID-19). - Patients with severe/life-threatening CRS may have cytopenias or elevated ALT/AST due to chemotherapy or CRS. Evaluate benefits vs. risks of short-term Actemra use. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Actemra is contraindicated in patients with a known hypersensitivity to tocilizumab or to any of the excipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common: Hypertension (Adult, 4-7%), Injection site disorder (Rheumatoid arthritis, 2.4-10.1% ; polyarticular juvenile idiopathic arthritis, 28.8% ; systemic juvenile idiopathic arthritis, 41.2%), Rash (Rheumatoid arthritis, 2-4%), Constipation (COVID-19, 6-13%), Diarrhea (Adults, COVID-19, 4-6% ; Pediatric, >5%), Nausea (COVID-19, 3-4%), Upper abdominal pain (Adult, 2-3%), ALT/SGPT level raised (COVID-19, 3% ; rheumatoid arthritis, 0.7-48%; polyarticular or systemic juvenile idiopathic arthritis, 4-13%), Aspartate aminotransferase serum level above reference range (Rheumatoid arthritis, 0.1-41%; polyarticular or systemic juvenile idiopathic arthritis, <1-5%), Dizziness (Adult, 2-3%), Headache (Adults, 3-7%; pediatric, >5%), Insomnia (COVID-19, 4-5%), Anxiety (COVID-19, 3-6%), Nasopharyngitis (Rheumatoid arthritis, 4-7%; systemic juvenile idiopathic arthritis, 5% or higher), Infusion reaction (Rheumatoid arthritis, 7-8%; polyarticular juvenile idiopathic arthritis, 16-20.2%). Serious: Septic shock (COVID-19, 6%), Gastrointestinal perforation, Pancreatitis, Neutropenia (Rheumatoid arthritis, 1.8-3.7% ; polyarticular or systemic juvenile idiopathic arthritis, 7-15.4%), Thrombocytopenia (Up to 4%), Hepatotoxicity, Anaphylaxis, Hypersensitivity reaction (Up to 0.9%), Opportunistic infection, Tuberculosis, Upper respiratory infection (Rheumatoid arthritis, 6-8%; systemic juvenile idiopathic arthritis, 5% or higher), Cancer, Sepsis, Severe infectious disease.                                                                                                                                                                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tocilizumab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

